Incidence of multiple myeloma (MM) has more than doubled globally since 1990, according to an analysis published in BMC Cancer. In order to evaluate the global disease burden, the investigators utilized 2019 data from the Global Burden of Disease study to calculate incidence, mortality, and disability adjusted life-years associated with MM. Read more…
Mayo Clinic today recognized the debut of a groundbreaking multi-cancer early cancer detection (MCED) test called Galleri™ that can detect more than 50 types of cancers through a simple blood draw. The Galleri test is intended to complement U.S. guideline-recommended cancer screenings. Mayo Clinic Oncologist Minetta Liu, M.D. was involved in the Read more…
More than a third of patients who progressed on osimertinib (Tagrisso) therapy for EGFR-positive non–small cell lung cancer (NSCLC) had a response to the combination of amivantamab (Rybervant) plus lazertinib, according to results of a cohort of the CHRYSALIS trial (NCT02609776) presented during the 2021 ASCO Annual Meeting. Biomarker analysis in Read more…
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed CAR-T therapy, demonstrated sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). Updated results from the Phase 1b/2 CARTITUDE-1 study (n=97) with a Read more…
In this single-arm, phase II study, the authors evaluated the use of 3 months of adjuvant capecitabine plus oxaliplatin (CAPOX) following curative-intent resection of colorectal liver metastases in 28 patients. The 5-year recurrence-free and overall survival rates were 65% and 87%, respectively. The use of 3 months of adjuvant CAPOX Read more…
The authors of this multicenter, noninferiority, phase III trial evaluated the safety and efficacy of oxaliplatin and capecitabine in elderly frail patients with advanced gastroesophageal cancer. Oxaliplatin and capecitabine were dosed at level A, level B (80% of level A), or level C (60% of level A) in the chemotherapy-intensive Read more…
A biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced open enrollment for its potentially pivotal study evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM. CNS’ lead product candidate, Berubicin, is Read more…
NORTH CHICAGO, Ill., May 19, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) will present results from 43 abstracts across 12 types of cancer during the upcoming virtual American Society of Clinical Oncology (ASCO) Annual Meeting (June 4-8) and the virtual European Hematology Association (EHA) congress (June 9-17). “We are advancing discovery and innovation Read more…
Multiple Myeloma (MM) is a heterogeneous cancer disease comprised of various distinct subtypes and accounts for nearly 20 percent of deaths caused by all blood related diseases. Treatment of this disease has improved over the last decades, however some patients continue to experience multiple relapses, which contribute to premature deaths. Read more…
Data from a new study by researchers at Fox Chase Cancer show that avapritinib, a platelet-derived growth factor receptor A (PDGFRA) inhibitor, has a “clinically meaningful benefit” for the treatment of gastrointestinal stromal tumors (GIST) with PDGFRA D842V mutations. According to lead author Margaret von Mehren, MD, chief of the Division of Sarcoma Medical Read more…